Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


13.11.2017

1 Cancer Res
6 Gynecol Oncol
1 Int J Cancer
1 J Natl Cancer Inst
1 Lancet Oncol
1 Obstet Gynecol
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Cancer Res

  1. CICHOCKI F, Valamehr B, Bjordahl R, Zhang B, et al
    GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
    Cancer Res. 2017;77:5664-5675.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  2. THAKER PH, Brady WE, Lankes HA, Odunsi K, et al
    A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary perito
    Gynecol Oncol. 2017 Aug 9. pii: S0090-8258(17)31186.
    PubMed     Text format     Abstract available

  3. RONCOLATO FT, Berton-Rigaud D, O'Connell R, Lanceley A, et al
    Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
    Gynecol Oncol. 2017 Oct 26. pii: S0090-8258(17)31422.
    PubMed     Text format     Abstract available

  4. MOORE KN, Tritchler D, Kaufman KM, Lankes H, et al
    Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31261.
    PubMed     Text format     Abstract available

  5. OZA AM, Tinker AV, Oaknin A, Shapira-Frommer R, et al
    Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
    Gynecol Oncol. 2017 Sep 4. pii: S0090-8258(17)31260.
    PubMed     Text format     Abstract available

  6. NASIOUDIS D, Chapman-Davis E, Frey MK, Caputo TA, et al
    Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base.
    Gynecol Oncol. 2017 Aug 10. pii: S0090-8258(17)31251.
    PubMed     Text format     Abstract available

  7. ALTMAN AD, McGee J, May T, Lane K, et al
    Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.
    Gynecol Oncol. 2017;147:257-261.
    PubMed     Text format     Abstract available


    Int J Cancer

  8. REGER MK, Zollinger TW, Liu Z, Jones JF, et al
    Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2017 Nov 8. doi: 10.1002/ijc.31095.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  9. DOHERTY JA, Jensen A, Kelemen LE, Pearce CL, et al
    Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    Lancet Oncol

  10. VENKATESAN P
    Possible origin of ovarian cancer in the fallopian tubes.
    Lancet Oncol. 2017 Nov 2. pii: S1470-2045(17)30834.
    PubMed     Text format    


    Obstet Gynecol

  11. BERCOW AS, Chen L, Chatterjee S, Tergas AI, et al
    Cost of Care for the Initial Management of Ovarian Cancer.
    Obstet Gynecol. 2017 Nov 3. doi: 10.1097/AOG.0000000000002317.
    PubMed     Text format     Abstract available


    PLoS One

  12. CHESNAIS M, Lecuru F, Mimouni M, Ngo C, et al
    A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer.
    PLoS One. 2017;12:e0187245.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: